MetaCap

Inventiva S.A. American Depository Shares (IVA) vs Syndax Pharmaceuticals (SNDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inventiva S.A. American Depository Shares (IVA) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 27.0% versus a loss of 50.0%. Over five years, SNDX leads with a -47.1% price change compared with -76.5% for IVA. Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $750.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IVA-26.98%SNDX-50.00%
+72%+8%-57%
Nov 21, 20251 yearNov 20, 2026
IVA-76.21%SNDX-50.90%
+66%-14%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IVA versus SNDX key metrics
MetricIVASNDX
Share price$3.14$8.72
Market cap$750.78M$785.05M
1-day change-8.99%-4.49%
YTD return-32.47%-58.50%
1-year return-26.98%-50.00%
5-year return-76.53%-47.09%
EPS (TTM)$-0.62$-2.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$172.35M
Revenue growth (YoY)—+627.84%
Net income (latest FY)$-49.63M$-285.42M
Operating margin—-158.45%
Net margin—-165.60%
52-week high$7.29$25.59
52-week low$2.82$8.41
Distance from 52-week high-56.93%-65.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+359.24%+306.54%
Average volume2.40M2.63M
Shares outstanding239.10M90.03M
Employees87298
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IVA has outperformed SNDX by 23.0 percentage points over the past year.

About Inventiva S.A. American Depository Shares

IVA stock →

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Syndax Pharmaceuticals

SNDX stock →

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees

IVA vs SNDX FAQ

Which is bigger, Inventiva S.A. American Depository Shares or Syndax Pharmaceuticals?

Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $750.78M for Inventiva S.A. American Depository Shares (IVA).

Which stock has performed better over the past year, IVA or SNDX?

IVA returned -26.98% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.

Are Inventiva S.A. American Depository Shares and Syndax Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons